Russian Heart Failure Journal 2008year Parameters of endothelial vasoregulatory function in patients with metabolic syndrome


To access this material please log in or register

Register Authorize
2008/

Parameters of endothelial vasoregulatory function in patients with metabolic syndrome

Mkrtumyan A. M., Biryukova E. V., Markina N. V.

Keywords:

DOI:

Urgency. Endothelial dysfunction is a marker of metabolic and vascular disorders. However studies of endothelial function in patients with metabolic syndrome (MS) are at initial steps. Aim. Studying parameters of endothelial function in patients with MS and determining the interrelation of endothelial dysfunction (ED) and major components of the syndrome. Materials and methods. 104 patients with MS were included in the study; 35 subjects without apparent disease made up a control group. Levels of glucose, immunoreactive insulin (IRI), TNF-α, endothelin-1 and NO metabolites in blood were measured in the fasting condition and after the oral glucose tolerance test (OGTT). Results. The MS was associated with pronounced ED. The glucose test resulted in decreased release of the vasodilatory factor, NO and increased level of the vasoconstrictory factor endothelin-1, in patients with MS. Levels of NO and endothelin-1 positively correlated with levels of the major markers for insulin resistance (hyperinsulinemia, HOMA index) and TNF-α in patients with MS.
    1.    Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-a nalysis of longitudinal studies. J Am Coll Cardiol. 2007;49 (4):403–414.
    2.    Hong Y, Jin X, Mo J. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality – results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med. 2007;262 (1):113–123.
    3.    Isomaa B, Lahti K, Almengren P et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24 (4):683–689.
    4.    Карпов Р. С. Современные проблемы атеросклероза: взгляд клинициста. Бюллетень сибирской медицины. 2003;3:13–29.
    5.    Никитин Ю. П., Казека Г. Р., Симонова Г. И. Распространенность компонентов метаболического синдрома Х в неорганизованной городской популяции (эпидемиологическое исследование). Кардиология. 2001;41 (9):37–40.
    6.    Widlansky ME, Gokce N, Keaney JF et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42 (7):1149–1160.
    7.    Park JH, Kwon HM, Roh JK. Metabolic syndrome is more associated with intracranial atherosclerosis than extracranial atherosclerosis Eur J Neurol. 2007;14 (4):379–386.
    8.    Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22 (6):423–436.
    9.    De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Lipidol. 2000;11 (1):9–23.
    10.    Irving RJ, Noon JP, Watt GC et al. Activation of the endothelin system in insulin resistance. QJM. 2001;94 (6):321–326.
    11.    Dallaire P, Marette A. Obesity-linked Insulin Resistance: Is Nitric Oxide the Missing Link? Can J Diabetes. 2004;28 (1):59–66.
    12.    Pilon G, Penfornis P, Marette A. Nitric oxide production by adipocytes: a role in the pathogenesis of insulin resistance? Horm Metab Res. 2000;32 (11–12):480–484.
    13.    Engeli S, Janke J, Gorzelniak K et al. Regulation of the nitric oxide system in human adipose tissue. J Lipid Res. 2004;45 (9):1640–1648.
    14.    Noronha BT, Li JM, Wheatcroft SB et al. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes. 2005;54 (4):1082–1089.
    15.    Chi-Chang J, Tung-Yueh C, Chih-Ling C et al. Endothelin-1 Regulates Adiponectin Gene Expression and Secretion in 3T3‑L1 Adipocytes via Distinct Signaling Pathways. Endocrinology. 2007;148 (4):1835–1842.
    16.    Piatti PM, Monti LD, Galli L et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism. 2000;49 (6):748–752.
    17.    Barton M, Kiowski W. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Curr Hypertens Rep. 2001;3 (4):322–330.
    18.    Cardillo C, Campia U, Kilcoyne CM et al. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation. 2002;105 (4):452–456.
    19.    Juan CC, Chuang TY, Chang CL et al. Endothelin-1 regulates adiponectin gene expression and secretion in 3T3‑L1 adipocytes via distinct signaling pathways. Endocrinology. 2007;148 (4):1835–1842.
    20.    Frustaci A, Kajstura J, Chimenti C et al. Myocardial cell death in human diabetes. Circ Res. 2000;87 (12):1123–1132.
    21.    Chan JC, Cheung JC, Stehouwer CD et al. The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome--an analysis by structural equation modelling. Int J Obes Relat Metab Disord. 2002;26 (7):994–1008.
    22.    Moller DE. Role of TNF in pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000;11 (6):212–217.
    23.    Kras KM, Hausman DB, Martin RJ. Tumor necrosis factor-alpha stimulates cell proliferation in adipose tissue-derived stromal-vascular cell culture: promotion of adipose tissue expansion by paracrine growth factors. Obes Res. 2000;8 (2):186–193.
    24.    Манухина E. Б., Дауни X. Ф., Маллет Р. Т., Малышев И. Ю. Защитные и повреждающие эффекты периодической гипоксии: роль оксида азота. Вестник Российской АМН. 2007;2:25–33.
    25.    Barbato JE, Zuckerbraun BS, Overhaus M et al. Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and metabolic syndrome. Am J Physiol Heart Circ Physiol. 2005;289 (1): H228–236.
    26.    Wilkes JJ, Hevener A, Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes. 2003;52 (8):1904–1909.
    27.    Ceriello A, Taboga C, Tonutti L et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation. 2002;106 (10):1211–1218.
    28.    Бирюкова Е. В., Дворяшина И. В., Литвинова Т. А. Гормональные и метаболические нарушения в постпрандиальном периоде при ожирении у лиц молодого возраста. Ожирение и метаболизм. 2005;2 (4):34–37.

To access this material please log in or register

Register Authorize
Ru En